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Abstract	
	Recently	recognised	forms	of	uveitis	include	intraocular	inflammations	that	occur	during	or	following	one	of	several	emerging	infectious	diseases:	chikungunya	fever,	dengue,	Zika	virus	disease	and	Ebola	virus	disease.	Anterior,	intermediate,	posterior	and	pan-	uveitis	have	been	described	in	individuals	infected	with	chikungunya	virus.	Persons	who	contract	dengue	or	Zika	viruses	also	may	develop	different	types	of	uveitis	in	the	course	of	the	infection:	maculopathy	is	a	common	manifestation	of	dengue	eye	disease,	and	Zika	eye	disease	may	cause	hypertensive	anterior	uveitis	or	mimic	a	white	dot	syndrome.	Up	to	one-third	of	Ebola	survivors	develop	aggressive	uveitis,	which	is	frequently	associated	with	vision	loss	and	complicated	by	cataract.	There	are	no	specific	anti-viral	drugs	for	these	forms	of	uveitis,	and	thus	treatment	is	largely	supportive.	In	this	article,	we	summarise	the	systemic	infectious	diseases	and	virology,	and	describe	the	clinical	presentations,	outcomes	and	management	of	emerging	viral	forms	of	uveitis.	
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Introduction		New	forms	of	eye	disease	continue	to	be	described	on	a	regular	basis,	in	large	part	due	to	the	considerable	advances	that	are	occurring	in	diagnostic	medicine,	as	well	as	in	biomedical	science.		In	the	field	of	uveitis	in	particular,	most	recent	new	diagnoses	have	been	in	the	area	of	infectious	uveitis,	including	re-definition	of	well-established	forms	of	uveitis	and	description	of	new	forms	associated	with	systemic	infections:	Fuchs	uveitis	syndrome	and	Possner-Schlossman	syndrome	have	been	linked	to	infections	with	rubella	virus	and	cytomegalovirus;	and	infections	with	human	immunodeficiency	virus,	Epstein-Barr	virus	and	Parvovirus	B19	have	been	associated	with	different	types	of	uveitis.1	Recently,	several	emerging	viral	infections	have	been	linked	to	uveitis.	Per	the	US	Centers	for	Disease	Control	and	Prevention	definition,	an	emerging	infection	is	one	“whose	incidence	in	humans	has	increased	in	past	2	decades	or	threatens	to	increase	in	the	near	future”	and	that	“respects	no	national	boundaries”.2	These	diseases	may	result	from:	(1)	evolution	of	existing	microbes;	(2)	appearance	of	new	infections	in	areas	that	are	changing	ecologically;	(3)	spread	of	infections	to	new	regions	or	population	groups;	and	(4)	re-emergence	of	pathogens	as	a	result	of	drug	resistance	or	failed	public	health	measures.2	The	emerging	virus	infections	that	have	been	linked	to	uveitis	include	Chikungunya	fever,	Dengue,	Ebola	virus	disease	and	Zika	infection.3-6			
Chikungunya	Fever		Overview	of	chikungunya	fever		Chikungunya	fever	is	the	infectious	disease	caused	by	chikungunya	virus	(CHIKV).7	Although	the	disease	has	been	identified	throughout	the	world	–	related	to	global	travel	
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–	it	is	endemic	in	Africa,	South	and	South-East	Asia,	India,	and	South	and	Central	America.8	Recent	outbreaks	between	2005	and	2007	in	India,	and	between	2014	and	2016	in	South	America	have	involved	millions	of	persons.9	The	virus	circulates	in	non-human	primate	and	small	mammal	reservoirs,	from	which	there	may	be	spread	to	humans.	It	is	carried	by	multiple	mosquito	species,	most	commonly	Aedes	aegypti	and	
Aedes	albopictus.7	The	majority	of	infected	individuals	become	symptomatic,	and	do	so	within	a	few	days	of	infection:	disease	is	characterized	by	a	high	fever,	headache,	rash,	myalgia	and	a	characteristic	arthralgia	for	which	chikungunya	virus	is	named.8	This	arthralgia	affects	the	extremities,	and	is	severe	and	deforming.	After	recovery,	approximately	one-half	of	affected	persons	develop	a	long-term	arthritis.	Fatality	of	chikungunya	fever	is	estimated	at	one	in	1000,	and	fatalities	generally	occur	in	very	young	or	elderly	patients,	or	in	adults	with	other	health	problems,	who	may	develop	multi-organ	involvement	including	encephalopathy.8	There	is	no	specific	anti-viral	drug	treatment	for	chikungunya	fever,	and	there	is	no	vaccination	that	protects	against	CHIKV.	Thus	treatment	is	supportive,	and	patients	with	chronic	arthritis	may	require	immunosuppression.8			Chikungunya	virology		Chikungunya	virus	is	a	member	of	the	Togaviridae	family	and	Alphavirus	genus,	and	consistent	with	the	systemic	manifestations	of	chikungunya	fever,	it	is	classified	in	the	Semliki	Forest	Virus	group	of	the	Old	World	alphaviruses.10	The	virion	is	spherical,	measuring	approximately	70	nm	in	diameter,	with	a	lipid	envelope	and	an	11.5	kb	positive-sense,	single-stranded,	RNA	genome.7,8	It	enters	different	cell	types,	such	as	those	in	muscle,	joints	and	skin,	via	receptor-mediated	endocytosis.7,8	The	CHIKV	RNA	genome	provides	transcripts	that	are	translated	into	the	non-structural	proteins	of	the	
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replication	complex,	which	transcribes	a	negative-sense	RNA,	and	subsequently	new	positive-sense	RNA	genomes	and	subgenomic	RNA.11,12	The	latter	are	translated	into	the	structural	elements	of	CHIKV:	capsid	and	envelope	glycoproteins,	E1	and	E2.	Viral	particles	are	assembled	at	the	cell	surface	from	cytoplasmic	encapsidated	RNA	genomes	and	glycosylated	E1/E2	proteins	arising	from	the	Golgi	apparatus,	with	new	virions	released	by	budding	at	the	cell	membrane.11,12		Chikungunya	fever-associated	uveitis		Although	non-specific	ocular	symptoms	–	including	photophobia	and	retro-orbital	pain	–	and	conjunctivitis	have	been	recognized	for	some	time	in	patients	with	chikungunya	fever,	the	first	descriptions	of	CHIKV-associated	uveitis	and	other	ocular	inflammatory	syndromes	were	published	just	10	years	ago,	following	the	large	outbreak	in	India.	Ophthalmic	clinical	groups	based	in	Tamil	Nadu	and	Bangalore	published	detailed	descriptions	of	uveitis,	keratitis	and	episcleritis,	and	neuroretinitis	and	optic	neuritis	that	began	within	4-6	weeks	of	the	onset	of	chikungunya	fever,	which	was	confirmed	through	serological	testing.3,13,14	A	recent	paper	from	the	same	region	–	that	coined	the	term,	“retinitis	post	febrile	illness”	or	“epidemic	retinitis”,	for	retinal	inflammation	occurring	in	seasonal-limited	outbreaks	in	tropical	regions	of	the	world	–	attributed	approximately	20%	of	this	condition	to	infection	with	CHIKV.15	Mahendradas	and	colleagues	have	published	a	comprehensive	review	of	the	ocular	manifestations	of	chikungunya	fever.16			Uveitis	is	the	most	common	ocular	involvement	reported	in	patients	with	chikungunya	fever.16	Anterior,	intermediate,	posterior	and	pan-	uveitis	all	have	been	reported	in	association	with	CHIKV	infection,	although	overall,	anterior	uveitis	is	the	most	
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common.3,13,17	The	anterior	uveitis	may	be	unilateral	or	bilateral;	both	granulomatous	and	non-granulomatous	forms	of	anterior	uveitis	occur,	and	pigmented	keratic	precipitates	are	a	frequent	feature.16	Iris	atrophy	does	not	appear	to	be	a	common	feature,	but	has	been	reported	in	the	form	of	bilateral	Fuchs’	heterochromic	iridocyclitis	with	iris	nodules	and	cataract.18	Intraocular	pressure	is	often	elevated.	Confocal	microscopy	shows	dendritic	keratic	precipitates.3	A	spectrum	of	posterior	uveitis	phenotypes	has	been	described	following	CHIKV	infection,	involving	one	or	both	eyes,	and	presenting	as	unifocal	or	multifocal,	retinitis	or	choroiditis.3,13,19	In	some	cases,	the	presentation	may	mimic	herpetic	retinitis.3	Retinal	vasculitis	may	occur,	and	may	be	complicated	by	retinal	haemorrhage	or	retinal	vascular	obstruction,3,13	and	optical	coherence	tomography	(OCT)-angiography	has	demonstrated	choriocapillaris	flow	deficits.20	Cystoid	macular	oedema	and	serous	retinal	detachment	may	complicate	the	inflammation.	Both	unilateral	and	bilateral	neuroretinitis	–	characterized	by	optic	disc	swelling	and	a	macular	star	–	have	been	reported.13,21	Acute	macular	neuroretinopathy	also	has	been	observed	in	the	context	of	chikungunya	fever,	with	wedge-shaped,	paracentral	macular	lesions.22					
	Other	forms	of	inflammatory	eye	disease	have	been	reported	in	patients	with	chikungunya	fever.	Keratitis	with	epithelial	dendrites,	mimicking	herpetic	keratitis,	but	occurring	bilaterally,	is	described.3	External	eye	manifestations	that	have	been	observed	include:	rheumatoid	factor-negative,	anti-nuclear	antibody-negative,	nodular	anterior	scleritis;	and	lagophthalmos	with	exposure	keratitis.13	Bilateral	and	unilateral	forms	of	optic	neuritis	are	possible,	including	papillitis,	retrobulbar	neuritis	and	retrochiasmal	neuritis.14	These	optic	neuropathies	cause	relative	afferent	pupillary	defects	and	colour	vision	deficits,	as	well	as	a	variety	of	visual	field	defects:	central	or	centrocaecal	
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scotomas,	peripheral	field	defects,	and	combined	central	and	peripheral	field	loss.	External	ophthalmoplegia	is	another	neuro-inflammatory	syndrome	reported	in	CHIKV-infected	patients.14		
	Making	the	diagnosis	of	CHIKV-associated	inflammatory	eye	disease	begins	with	information	from	the	history,	including	residence	in	or	recent	travel	to	an	endemic	area,	and	recent	febrile	illness	with	typical	musculoskeletal	symptoms.	The	inflammatory	eye	disease	is	often	non-specific,	although	presentations	mimicking	herpetic	uveitis,	but	occurring	bilaterally,	may	raise	the	suspicion.	In	several	published	series,	systemic	testing	has	involved	serological	testing	for	CHIKV	immunoglobulin	(Ig)	M,3,13,14	which	is	generally	detectable	within	the	first	week	and	for	multiple	months	after	the	onset	of	the	systemic	illness.8	Although	reverse	transcription	(RT)-	polymerase	chain	reaction	(PCR)	for	virus	is	commonly	used	to	diagnose	the	systemic	illness,8	it	may	be	less	useful	for	the	eye	disease,	since	this	may	present	after	the	resolution	of	the	viraemia.	Several	reports	have	described	the	successful	use	of	RT-PCR	analysis	of	aqueous	to	detect	viral	RNA	in	cases	of	CHIKV-associated	anterior	uveitis.18,23	Ruling	out	forms	of	uveitis	that	may	mimic	the	presentation,	is	a	standard	principle	when	assessing	any	form	of	uveitis,	and	thus	testing	for	herpetic	viruses	in	particular,	plus	other	locally	endemic	viruses,	as	well	as	the	masqueraders,	syphilis	and	tuberculosis,	may	be	appropriate.		
	When	treatment	has	been	given	to	persons	with	CHIKV-associated	inflammatory	eye	disease,	this	generally	has	been	directed	at	the	inflammation	and/or	its	complications.	Patients	with	anterior	uveitis	have	been	treated	with	topical	prednisolone	acetate,	diclofenac	sodium,	as	well	as	a	topical	cycloplegic	and	topical	anti-glaucoma	drops.3,13	Episcleritis	has	been	managed	with	topical	diclofenac	sodium	and	systemic	
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indomethacin.3	For	posterior	eye	involvements,	including	uveitis	and	optic	neuritis,	patients	have	been	treated	with	oral	prednisolone,	preceded	by	intravenous	methylprednisolone	for	optic	nerve	involvement.3,13,14	Some	patients	with	retinal	involvement	also	have	been	given	acyclovir.3	Since	this	drug	does	not	have	anti-CHIKV	activity,	therapeutic	effect	seems	unlikely,	and	the	primary	value	would	be	to	cover	the	possibility	of	a	herpetic	infection	in	cases	of	retinitis.		
	Ocular	inflammation	in	chikungunya	fever	typically	resolves	within	approximately	3	months.16	Patients	initially	present	with	a	wide	range	of	visual	acuities,	from	normal	to	6/60	or	worse,	including	perception	of	only	hand	movements	or	light.3,13,14	Typically	anterior	segment	disease	is	associated	with	good	visual	acuity,	while	posterior	segment	disease	is	not,	but	there	are	exceptional	cases	of	good	vision	in	patients	who	present	with	posterior	uveitis,	neuroretinitis	and	optic	neuritis.	There	is	similarly	a	wide	range	of	visual	acuities	measured	following	resolution	of	the	inflammation,	although	a	majority	of	patients	retain	or	recover	vision.3,13,14	Poor	outcomes	typically	occur	in	patients	with	optic	neuritis,	particularly	when	presentation	is	delayed.14			
Dengue	
	Overview	of	Dengue		The	most	common	vector-borne	disease,	dengue,	affects	an	estimated	390	million	persons	annually.24	Half	the	global	population	live	in	areas	of	transmission,	and	three-quarters	of	these	people	reside	in	the	Asia-Pacific	region.25	Dengue	virus	(DENV)	exists	as	four	serotypes	(i.e.	DENV1,	DENV2,	DENV3	and	DENV4),	all	of	which	are	capable	of	epidemic	spread.26	While	infection	confers	lifelong	immunity	to	the	infecting	serotype,	
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subsequent	infection	with	a	different	serotype	may	be	severe,	since	antibodies	may	not	effectively	neutralize	the	virus,	and	instead	facilitate	its	entry	into	the	cell	and	enhance	viral	production.25	Classification	of	the	infectious	disease	has	been	simplified	to	dengue,	with	warning	signs,	and	severe	dengue.27	Up	to	a	week	after	the	bite	of	infected	Aedes	species	mosquitoes,	individuals	develop	fever,	rash,	myalgia	and	arthralgia	that	can	last	for	7	days	before	defervescence.	The	48-hour	critical	phase	follows,	during	which	vascular	and	metabolic	derangements	may	occur,	and	supportive	care	in	the	form	of	fluid	replacement	may	be	required.	Convalescence	may	be	associated	with	hepatic	and	cardiac	complications,	and	post-viral	fatigue.	No	anti-viral	drugs	are	effective	against	DENV.	The	first	vaccine	was	registered	in	2015,	but	this	was	linked	to	reports	of	deaths:	post-hoc	analysis	identified	a	subgroup	of	DENV-naïve	children	who	were	paradoxically	at	higher	risk	of	severe	dengue	after	vaccination.28	While	mortality	from	dengue,	with	intravenous	rehydration	when	appropriate,	should	be	near	zero,	reported	deaths	have	increased	over	the	last	decade	and	the	average	case-fatality	rate	is	2.5%.26		
	Dengue	virology	Dengue	virus	–	which	is	a	member	of	the	Flaviridae	family	and	Flavivirus	genus	–	is	relatively	small,	at	50	nm	in	size.25,29	A	lipid	envelope	encloses	the	nucleocapsid,	housing	an	11	kb	single-stranded	positive-sense	RNA	genome.29	Using	receptor-mediated	endocytosis	to	enter	cells,	DENV	binds	the	C-type	lectin	CD209	antigen	receptor	on	the	dendritic	cell,	which	is	its	primary	target,	and	uses	phosphatidylserine	receptors	on	epithelial	and	other	cells.25	Within	the	endosome,	pH-dependent	fusion	allows	release	of	viral	RNA	into	the	cytoplasm.	The	genome	is	translated	into	a	polyprotein	and	cleaved	by	host	and	viral	proteases	to	produce	three	structural	and	7	non-structural	proteins.29	The	replication	strategy	of	DENV	is	to	hijack	the	endoplasmic	reticulum,	remodeling	it	to	
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create	invaginations	that	protect	from	host	recognition.25	Within	these	pockets,	viral	genomic	RNA	and	structural	proteins	are	mass-produced.	Virions	are	assembled,	and	subsequently	taxied	through	the	increasingly	acidic	trans-Golgi	network,	before	being	released	as	mature	virus	particles	from	the	cell	through	exocytosis.		Dengue-associated	uveitis	A	spectrum	of	ocular	disease	associated	with	DENV	infection	has	been	reported	in	the	literature,	ranging	from	haemorrhagic	to	inflammatory	manifestations.30	The	most	common	ocular	complications	involve	haemorrhage.	Conjunctival	haemorrhage	is	widespread	amongst	persons	with	dengue,	but	visually	significant	haemorrhagic	complications	involve	the	posterior	segment	of	the	eye.	Uveitis	has	been	associated	with	dengue,	and	is	diverse	in	its	presentation.30	Anterior	uveitis	is	reported	to	affect	infected	persons	who	are	otherwise	healthy,	and	may	present	up	to	5	months	after	onset	of	systemic	symptoms.	Visual	recovery	is	favourable	with	topical	corticosteroid	therapy	and	cycloplegia.	Posterior	and	panuveitis	usually	present	within	the	first	few	weeks	of	systemic	symptoms.	Patients	may	be	systemically	unwell:	serous	retinal	detachments	with	panuveitis	have	been	described	in	association	with	hepatitis,	pericarditis	and	severe	hypokalaemia.31,32	Choroidal	effusions	can	be	extreme	and	have	been	described	in	a	patient	presenting	with	bilateral	acute	secondary	angle	closure.33		Causes	of	visual	symptoms	in	patients	with	DENV	infection	are	variable,	but	commonly	reflect	macular	involvement.	During	the	2004-2005	Singapore	epidemic,	a	majority	of	50	symptomatic	ophthalmology	outpatients	complained	of	blurred	vision,	and	one-third	reported	visual	field	defects.30	Macular	oedema	occurred	in	three-quarters	of	these	individuals,	while	macular	haemorrhages	were	present	in	two-thirds,	and	vasculitis	was	
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documented	in	one-quarter.	Of	those	who	had	daily	platelet	levels,	all	became	visually	symptomatic	within	one	day	of	their	lowest	count.	A	smaller	study	during	the	same	epidemic	found	bilateral	but	asymmetric	macular	disease	in	three-quarters	of	symptomatic	patients	presenting	to	eye	services.34	Almost	two-thirds	of	these	patients	presented	with	central	or	paracentral	scotomas.	Retinal	venous	occlusions	occurred	in	25%	of	eyes;	venular	sheathing	was	observed	in	45%;	and	arteriolar	sheathing	was	present	in	4%.	Foveolitis	–	with	a	yellow	or	orange	subretinal	dot	–	is	a	particularly	characteristic	form	of	dengue	maculopathy	that	was	documented	in	28%	of	the	patients.34		Cross-sectional	studies	performed	during	epidemics	provide	the	best	estimate	of	the	prevalence	of	dengue-associated	maculopathy.	During	the	2005	Singapore	epidemic,	DENV1	was	the	most	common	circulating	serotype,	and	during	this	time	nearly	200	hospital	inpatients	with	dengue	were	examined	ophthalmoscopically.4	While	persons	in	the	community	and	those	with	life-threatening	thrombocytopaenia	were	excluded	from	examination,	maculopathy	was	present	in	10%	of	this	DENV-seropositive	patient	group.	Affected	individuals	had	a	mean	complement	C3	level	that	was	significantly	lower	than	levels	measured	in	those	without	maculopathy.	Curiously,	those	with	maculopathy	tended	to	be	young	adults,	and	were	either	asymptomatic	or	had	ignored	their	symptoms.	A	similar,	albeit	smaller	cross-sectional	study	conducted	during	the	2007	Singapore	epidemic,	when	DENV2	was	the	predominate	serotype	in	circulation,	identified	no	cases	maculopathy	in	DENV-seropositive	inpatients.35	These	individuals	tended	to	be	older,	and	had	milder	liver	impairment	compared	to	the	2005	cohort,	suggesting	that	maculopathy	and	ocular	complications	might	be	related	to	DENV	serotype	or	virulence.			
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The	tissue	features	of	dengue-related	maculopathy	have	been	examined	in	a	study	that	employed	Fourier-domain	OCT	to	image	the	retinae	of	74	eyes	from	41	patients.36	Visual	changes	tended	to	coincide	with	the	nadir	of	thrombocytopaenia,	about	7	days	after	onset	of	systemic	symptoms.	Three	phenotypes	of	maculopathy	were	described:	Type	1,	diffuse	retinal	thickening;	Type	2,	cystoid	macular	oedema;	and	Type	3,	foveolitis	with	outer	retinal	thickening	and	hyper-reflectivity.	All	Types	were	associated	with	scotomas,	and	at	2	years,	60%	of	eyes	had	persistent	scotomas.	“Doughnut”	scotoma	were	typical	of	eyes	with	Type	3	maculopathy,	all	of	which	retained	visual	field	defects	at	2	years.			Retinal	vasculitis	usually	presents	within	a	week	of	systemic	symptoms	in	patients	who	may	have	thrombocytopaenia,	but	are	otherwise	well,	and	visual	recovery	depends	on	the	degree	of	maculopathy	and	ischaemia.37	Presentations	of	posterior	uveitis	affect	the	outer	retina,	and	include	acute	posterior	multifocal	placoid	pigment	epitheliopathy,	acute	zonal	occult	outer	retinopathy	and	retinochoroiditis.38-40	Cases	of	acute	macular	neuroretinopathy	have	been	reported	in	patients	with	dengue.41	Persistent	scotomas	with	a	normal	ocular	examination	have	also	been	documented.	Electrophysiological	studies	have	confirmed	involvement	of	the	middle	and	outer	retina	in	DENV-associated	retinopathy,	usually	affecting	the	fovea,	and	with	relative	sparing	of	the	inner	retina.42		The	long-term	visual	prognosis	of	DENV-related	ocular	complications	is	variable,	but	most	patients	have	a	positive	outcome.43	One	study	of	65	eyes	of	50	consecutive	patients	with	DENV	infection	and	a	spectrum	of	ocular	complications	showed	that	over	80%	of	patients	had	a	visual	acuities	of	6/12	or	better	at	one	year.30	Thirteen	patients	with	panretinal	vasculitis	were	treated	with	systemic	corticosteroids,	including	6	individuals	who	took	a	course	of	oral	prednisolone,	and	7	individuals	were	also	treated	with	pulsed	
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intravenous	methylprednisolone.	No	adverse	effects	were	reported,	but	despite	treatment,	11	eyes	of	7	patients	treated	with	intravenous	corticosteroid	had	visual	acuities	between	6/12	and	6/60	at	final	follow-up.	Those	with	anterior	segment	inflammation	had	a	more	favourable	course,	and	7	individuals	treated	with	topical	corticosteroid	experienced	resolution	at	one	week	with	no	relapse	after	cessation.	A	separate	study	of	DENV-related	maculopathy	detailed	visual	recovery	in	a	cohort	of	patients	who	were	managed	expectantly.36	Overall,	visual	acuity	improved	from	better	than	6/12	in	42%	of	eyes	at	presentation,	to	62%	at	1	month,	and	over	80%	at	2	years.	Those	who	presented	with	foveolitis	had	a	relatively	poor	prognosis,	with	approximately	one-half	of	eyes	recovering	visual	acuity	to	6/12	or	better,	and	all	patients	reporting	persistent	scotomas.		An	infection	with	DENV	may	be	confirmed	by	detecting	viral	RNA	in	the	serum	using	RT-PCR	from	up	to	48	hours	before	the	onset	of	fever	until	6	days	following	the	onset	of	constitutional	sympyoms.25	Serologic	testing	may	identify	DENV	antibodies	after	this	time:	DENV	IgM	appear	within	the	week	after	fever	begins	and	persist	for	approximately	3	months26,	while	DENV	IgG	develop	more	slowly,	unless	infection	is	secondary.44	Ocular	fluids	may	be	tested	in	case	of	diagnostic	uncertainty,	although	there	were	no	PCR-confirmed	DENV	infections	in	one	published	report	that	involved	aqueous	sampling	in	cases	of	epidemic	retinitis.15	
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Zika	virus	disease	
	Overview	of	Zika	virus	disease	From	its	discovery	in	Uganda	in	1947,	Zika	virus	(ZIKV)	caused	only	14	documented	cases	of	human	infection	until	2007,	when	an	outbreak	of	rash,	arthralgia	and	conjunctivitis	occurred	in	Yap	Island,	Micronesia.45	Almost	three-quarters	of	residents	had	serological	evidence	of	ZIKV	infection.45	Six	years	later,	ZIKV	infected	30,000	people	in	French	Polynesia,	and	by	early	2015,	ZIKV	had	reached	South	America46.	During	the	2015-2016	South	American	epidemic,	40,000	pregnant	women	were	infected	with	ZIKV,	and	4,000	diagnoses	of	ZIKV-associated	microcephaly	were	confirmed	in	Brazil.47	Now	an	official	teratogen,	ZIKV	can	be	transmitted	sexually	and	transplacentally.48	Pregnant	women	who	contract	ZIKV	risk	preterm	birth,	miscarriage,	and	a	congenital	Zika	syndrome	that	consists	of	intrauterine	growth	retardation,	microcephaly,	brain,	auditory,	skeletal,	and	ocular	abnormalities.49	Children	with	congenital	Zika	syndrome	have	widespread	functional	disabilities	and	an	unknown	prognosis.49		Like	DENV,	ZIKV	is	transmitted	by	the	daytime-biting	Aedes	mosquito	species.25	Incubation	lasts	up	to	two	weeks,	and	infection	is	subclinical	in	80%	of	individuals.45	The	most	common	symptom	is	a	maculopapular	rash,	which	may	be	accompanied	by	low-grade	fever,	malaise,	headache,	non-purulent	conjunctivitis,	myalgia,	and	arthralgia,	lasting	up	to	a	week.50	There	is	currently	no	vaccine	against	ZIKV,	and	treatment	is	supportive.	In	adults,	the	major	complication	of	ZIKV	infection	is	Guillain-Barré	syndrome,	an	acute	immune-mediated	migrating	polyradiculopathy	affecting	motor	and	sensory	functions,	usually	occurring	within	a	week	of	viral	symptoms.46	The	French	
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Polynesian	epidemic	was	responsible	for	a	20-fold	increase	in	Guillain-Barré	syndrome,	with	an	estimated	risk	of	0.24	per	1,000	ZIKV	infections.46			Zika	virology				Zika	virus	has	two	lineages	that	circulate	in	different	cycles.51	In	Africa,	ZIKV	propagates	through	sylvatic	transmission	-	between	Aedes	mosquito	vectors	and	non-human	primate	reservoirs,	and	humans	are	sporadic	hosts.	Beyond	Africa,	ZIKV	cycles	through	urban	transmission	between	domesticated	Aedes	aegypti	vectors	and	human	reservoirs.	Like	DENV,	ZIKV	is	a	single-stranded	RNA	flavivirus,	which	shares	many	features.	Zika	virus	has	a	lipid	envelope	enclosing	its	nucleocapsid,	and	an	11	kb	genome.50	It	displays	an	affinity	for	neural	progenitor	cells	and	the	capacity	to	infect	a	broad	range	of	cell	types.52	The	virion	enters	the	cell	through	endocytosis,	and	within	the	cytoplasm,	the	genome	is	translated	into	one	polyprotein	and	cleaved	to	produce	three	structural	and	7	non-structural	proteins	that	are	required	for	viral	replication	and	the	formation	of	new	virus	particles.50			Zika	virus-associated	uveitis	Infants	with	congenital	Zika	syndrome	present	with	a	range	of	ocular	abnormalities,	but	the	two	classic	retinal	appearances	are	well-circumscribed	atrophy	and	pigment	mottling	at	the	macula.53	Regardless	of	ocular	involvement,	all	infants	with	congenital	Zika	syndrome	have	displayed	significant	visual	impairment,	suggesting	that	cortical	rather	than	ocular	dysgenesis	is	the	most	common	cause	of	blindness.49	In	adults,	ocular	complications	of	ZIKV	infection	tend	to	be	mild	and	self-limiting.	Retro-orbital	pain	and	conjunctivitis	are	common,	affecting	40%	in	one	study54.	Uveitis	is	an	uncommon	
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complication	of	ZIKV	infection,	with	less	than	20	cases	published	in	the	literature.	Visual	outcomes	are	favourable,	and	recurrence	has	not	been	documented.		Anterior	uveitis	in	ZIKV	infection	is	associated	with	high	intraocular	pressure.5,55,56	A	39-year	old	male	Brazilian	physician	presented	one	week	after	the	onset	of	constitutional	symptoms	with	bilateral	hypertensive	anterior	uveitis	that	completely	resolved	with	anti-hypertensive	and	corticosteroid	eye	drops.55	A	similar	report	described	a	male	presenting	with	bilateral	anterior	uveitis	8	days	after	onset	of	a	rash.	Remarkably,	ZIKV	was	confirmed	through	RT-PCR	of	aqueous	fluid	taken	by	anterior	chamber	paracentesis.5	Upon	review	after	a	further	8	days,	the	uveitis	had	responded	to	topical	corticosteroid,	and	no	virus	was	detected	in	a	second	paracentesis.	Two	patients	were	described	with	bilateral	acute	hypertensive	anterior	uveitis,	occurring	10	days	after	onset	of	systemic	symptoms.56	Aqueous	tested	negatively	for	ZIKV	by	RT-PCR	in	one	patient,	but	positively	in	the	other.	The	uveitis	in	both	patients	improved	with	topical	corticosteroids	and	anti-hypertensive	drugs.	In	all	patients,	visual	acuity	returned	to	baseline	with	the	topical	treatment.		Various	presentations	of	posterior	uveitis	have	been	described	in	association	with	ZIKV	infection.57-61	A	healthy	20-year	old	woman	in	Trinidad	presented	with	bilateral	neuroretinitis	during	the	2015-2016	South	American	ZIKV	epidemic.57	Her	ocular	symptoms	began	a	month	after	a	viral	illness,	and	she	presented	with	a	relative	afferent	pupil	defect,	and	bilateral	optic	disc	oedema	and	macular	stars.	All	investigations,	including	MRI	brain,	were	normal	with	the	exception	of	serum	ZIKV	IgM.	Subsequent	clinical	course	was	not	reported.	An	woman	living	in	Puerto	Rico	during	the	same	epidemic,	who	was	immunocompromised	following	chemotherapy	for	lymphoma,	
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presented	with	bilateral	panuveitis,	including	chorioretinal	lesions	suggestive	of	acute	posterior	multifocal	placoid	pigment	epitheliopathy.58	Diagnostic	anterior	chamber	paracentesis	excluded	herpes	simplex	virus	and	cytomegalovirus;	Toxoplasma	gondii	and	DENV	serology	were	negative;	and	recurrent	lymphoma	was	excluded.	Serum	ZIKV	RT-PCR	confirmed	the	diagnosis,	and	the	anterior	chamber	inflammation	was	treated	with	topical	corticosteroids.	After	5	months,	visual	acuity	had	finally	returned	to	baseline,	and	the	chorioretinal	lesions	were	healed.			A	healthy	26-year	old	tourist	returning	from	Puerto	Rico	in	2016	presented	with	bilateral	posterior	uveitis,	one	week	after	the	onset	of	systemic	symptoms,	when	aqueous	fluid	tested	negatively	for	ZIKV.59	There	were	peripheral	chorioretinal	lesions,	which	appeared	nodular	and	were	hyperfluorescent,	and	appeared	hyperreflective	by	OCT.	While	the	visual	acuity	remained	at	6/6,	he	was	mildly	symptomatic	of	the	eye	involvement.	Unilateral	anterior	vitreous	cells	were	treated	with	a	short	course	of	topical	corticosteroid,	and	the	choroidal	lesions	showed	evidence	of	regression	by	5	months.	Two	case	reports	describe	men	with	unilateral	acute	idiopathic	maculopathy,	presenting	10	days	after	onset	of	systemic	features.60,61	Both	had	unilateral	loss	of	vision,	and	disruption	of	the	outer	retinal	and	retinal	pigment	epithelial	architecture	on	OCT.	Symptoms	resolved,	and	visual	acuity	returned	to	baseline	with	conservative	management.	At	final	follow-up,	one	patient	had	residual	changes	in	the	ellipsoid	zone	of	the	retina	at	3	weeks,	while	the	other	had	a	normal	OCT	at	6	weeks.		Zika	virus	has	been	isolated	in	tears	during	the	acute	phase	of	infection.	Eleven	Chinese	tourists	to	Venezuela	returned	with	serum	RT-PCR-confirmed	ZIKV.	Their	serum	viral	load	was	undetectable	after	5	days	of	symptoms,	whereas	conjunctival	swab	samples	
	 18	
contained	ZIKV	until	the	7th	day	after	fever	onset.62	A	study	in	Singapore	of	29	individuals	with	serum	and/or	urine	RT-PCR-confirmed	infection	found	ZIKV	RNA	in	10%	of	conjunctival	swabs	one	month	after	fever	onset.63	These	patients	had	been	symptomatic	with	either	conjunctivitis	or	retro-global	pain.			The	diagnosis	of	ZIKV-associated	uveitis	is	challenging.	For	individuals	returning	from	tropical	regions,	the	differential	diagnosis	includes	DENV	and	CHIKV-related	disease.	Due	to	a	lack	of	symptoms	in	the	majority	of	ZIKV	infections,	an	index	of	suspicion	is	required	to	diagnose	ZIKV	uveitis	in	those	presenting	with	undifferentiated	anterior	uveitis	and	a	history	of	travel	to	endemic	regions.	Using	RT-PCR,	viral	RNA	can	be	detected	from	serum	during	viraemia	that	occurs	a	few	days	before	symptom	onset	and	may	last	up	to	a	week64.	As	viraemia	wanes,	serum	IgM	can	be	detected	from	2	to	12	weeks	after	exposure	using	IgM	capture	enzyme-linked	immunosorbent	assay.64	Ocular	fluid	testing	has	aided	diagnosis	in	ZIKV	anterior	uveitis,	but	the	virus	is	variably	detected	using	RT-PCR.5,59	Comparison	of	serum	and	intraocular	levels	of	anti-ZIKV	antibody	using	the	Goldmann-Witmer	coefficient	has	not	been	described,	but	might	be	a	useful	tool	for	diagnosis.		
Ebola	virus	disease	
	Overview	of	Ebola	virus	disease	The	2014-2016	West	African	Ebola	epidemic	affected	28,500	individuals	and	claimed	over	11,000	lives.65	Prior	to	this	epidemic,	13	outbreaks	with	a	total	of	1,460	cases	of	
Zaire	ebolavirus	(EBOV)	infections	had	been	documented	since	its	discovery	in	1976.66	Although	the	bat	is	assumed	to	be	the	reservoir	for	EBOV,	transmission	also	occurs	by	
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direct	contact	between	infected	individuals	or	animals.	Ebola	virus	disease	is	a	haemorrhagic	illness	that	manifests	up	to	3	weeks	after	infection,	initially	as	fever,	sore	throat,	headache,	myalgia	and	fatigue.67	Diarrhoea,	vomiting,	rash	and	bleeding	complications	follow.	Diagnosis	generally	involves	detection	of	viral	RNA	by	RT-PCR	in	the	blood.	Hepatic,	respiratory	and	renal	impairments	are	common,	and	death	results	from	shock,	with	electrolyte,	metabolic	and	coagulation	derangements.	The	case	fatality	rate	in	the	West	Africa	epidemic	ranged	up	to	74%,	while	those	individuals	repatriated	to	Europe	and	the	US	for	treatment	experienced	a	survival	rate	close	to	90%.67	Survivors	begin	to	recover	a	few	weeks	after	the	onset	of	symptoms,	but	the	persistence	of	live	EBOV	in	immune-privileged	sites,	such	as	reproductive	organs,	placenta	and	central	nervous	system,	poses	an	enormous	burden	for	public	health.	Survivors	also	experience	severe	fatigue,	myalgia,	arthralgia,	gastric	pain,	auditory	and	psychiatric	sequelae,	as	well	as	ocular	complications.68			Treatment	of	Ebola	virus	disease	is	supportive,	and	no	anti-viral	drugs	have	proven	to	be	effective.	A	vaccine	expressing	EBOV	surface	glycoprotein	in	a	recombinant	vesicular	stomatitis	virus	vector	was	implemented	in	three	phase	II/III	trials	across	West	Africa	in	2015.69	These	trials	were	designed	to	deliver	the	vaccine	to	high-risk	populations,	while	also	evaluating	safety	and	efficacy	data.	In	Sierra	Leone,	almost	8,000	participants	were	immunized	in	a	randomized,	non-blinded,	ring-vaccination	trial	without	placebo.70	No	participants	contracted	Ebola	virus	infection,	and	there	were	no	vaccine-related	serious	adverse	events.	This	was	a	remarkable	feat	considering	the	challenge	of	conducting	a	large	trial	in	developing	countries	during	a	global	health	crisis.	
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Ebola	virology				The	Ebolavirus	genus	falls	within	the	Filoviridae	family	and	Mononegavirales	order,	and	describes	enveloped,	non-segmented,	negative-polarity	RNA	viruses.71	Five	antigenically-distinct	Ebola	species	have	been	identified:	Zaire,	Sudan,	Reston,	Tai	Forest,	and	Bundibugyo	ebolavirus.	Zaire	ebolavirus	is	responsible	for	the	most	epidemics,	and	has	three	recognized	strains,	of	which	Makona	was	the	causative	agent	in	the	2014-2016	West	Africa	epidemic.65	Named	for	the	filamentous	form,	EBOV	is	relatively	large,	with	a	diameter	of	98	nm	and	a	length	that	may	extend	beyond	20	µm.71	The	genome	is	19	kb	long,	encoding	7	genes	and	exhibiting	polyploidy,	harbouring	multiple	copies	of	the	genome	within	an	extremely	long	virus.71	The	virion	attaches	to	a	variety	of	host	cell	surface	molecules,	is	assumed	into	the	endosome,	and	finally	released	into	the	cell	cytoplasm.	Transcription,	translation	and	replication	of	the	genome	occur	in	the	cytoplasm,	producing	virions	that	bud	from	the	host	cell	surface.	
		Post-Ebola	uveitis	The	association	of	uveitis	with	Ebola	virus	disease	was	widely	recognized	with	the	case	of	the	US	physician	repatriated	from	Sierra	Leone	in	2014	with	Ebola	virus	disease.72	He	survived	multi-organ	failure,	and	9	weeks	after	resolution	of	viraemia	presented	with	photophobia	and	a	foreign	body	sensation.	He	had	no	intraocular	inflammation	at	that	time,	but	was	noted	to	have	multiple	scattered	peripheral	chorioretinal	scars.	One	month	later,	he	presented	with	a	unilateral	hypertensive	anterior	uveitis	that	progressed	despite	intensive	topical	treatment,	and	was	complicated	by	iris	heterochromia.	An	anterior	chamber	paracentesis	was	performed,	and	EBOV	was	detected	in	the	aqueous	fluid	by	RT-PCR	and	culture.	Concurrently,	a	conjunctival	swab	and	tear	sample	both	returned	negative	for	viral	RNA.	The	ocular	condition	deteriorated,	
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with	scleritis	and	panuveitis,	and	the	patient	was	treated	with	systemic	corticosteroids	and	an	experimental	anti-viral	drug,	favipiravir.	Three	months	after	onset,	the	uveitis	resolved,	the	iris	heterochromia	reversed,	and	the	visual	acuity	returned	to	6/4.8.	A	similar	case	in	2014	involved	another	US	physician,	who	was	evacuated	from	Liberia	with	EBOV	infection.73	He	presented	two	weeks	after	discharge	from	hospital,	and	40	days	after	the	onset	of	Ebola	virus	disease,	with	a	unilateral	anterior	uveitis	that	worsened	to	involve	the	posterior	segment	with	vitritis	and	macular	oedema.	He	was	HLA-B27-positive.	After	treatment	with	oral	prednisolone,	visual	acuity	improved	from	6/60	to	6/6.	He	did	not	have	an	anterior	chamber	paracentesis	to	investigate	for	intraocular	virus,	but	EBOV	RNA	was	detected	by	RT-PCR	in	a	semen	sample.		Prior	to	the	2014-2016	West	African	outbreak,	uveitis	had	been	associated	with	EBOV	infection.	During	the	1995	EBOV	epidemic	in	the	Democratic	Republic	of	Congo,	uveitis	was	observed	in	3	of	20	survivors,	and	a	fourth	case	was	also	reported.74	These	patients	had	anterior,	posterior	and	pan-	uveitis,	presenting	42	to	72	days	after	onset	of	th	systemic	symptoms.	Another	series	of	19	survivors	of	that	epidemic	reported	one	case	of	uveitis.75	The	uveitis	and	visual	recovery	were	not	described	in	detail.				Ocular	symptoms	after	Ebola	virus	disease	are	common,	involving	up	to	60%	of	survivors	in	Sierra	Leone.68,76	A	study	of	96	Ebola	virus	disease	survivors	in	Liberia	found	that	three-quarters	reported	blurry	vision,	while	over	half	reported	photophobia,	tearing	and/or	eye	pain.6		However,	the	main	ocular	complication	of	EBOV	infection	was	uveitis,	with	over	180	cases	being	documented	in	survivors	of	the	2014-2016	West	African	epidemic.6,68,72,76-79	Reported	rates	of	uveitis	in	Ebola	survivors	vary,	but	the	condition	may	affects	as	many	as	one-third	of	these	individuals,	who	present	on	average	
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3	to	8	weeks	after	discharge	from	the	Ebola	treatment	unit.68,76,77	Risk	factors	for	developing	uveitis	include	a	high	viral	load	whilst	in	the	treatment	unit,	presumed	conjunctivitis	during	the	acute	phase	of	disease	and	older	age.68,74,76	In	one	study,	uveitis	was	10	times	more	likely	if	survivors	had	experienced	red	eyes	during	their	acute	disease.68	Length	of	admission	to	the	treatment	unit,	and	systemic	manifestations	–	including	hair	loss,	hearing	impairment,	arthralgias	and	arthritis	–	were	not	associated	with	the	development	of	uveitis.6			In	the	2014-2016	West	African	epidemic,	uveitis	was	most	often	unilateral,	but	bilateral	disease	was	also	observed.76	Anatomic	location	was	anterior	in	almost	half	of	cases,	while	posterior	and	pan-	uveitis	each	accounted	for	approximately	one-quarter.76,77	Most	patients	were	treated	with	local	and	systemic	corticosteroids	and	cycloplegia,	and	recurrences	were	reported,	but	uncommon.77,80	Other	ocular	manifestations	in	survivors	included	episcleritis,	interstitial	keratitis,	nystagmus,	motility	disorders	and	optic	neuropathy.6,77	Hyperpigmented	retinal	pigment	epithelial	scars	with	hypopigmented	borders	are	more	common	in	survivors	who	develop	uveitis.6		The	visual	prognosis	for	Ebola	survivors	is	poor,	and	those	who	develop	uveitis	have	significantly	worse	vision	than	those	who	do	not.	In	one	study	of	96	survivors,	nearly	40%	of	those	with	uveitis	were	blind,	and	vision	was	significantly	worse	in	these	patients	compared	to	those	without	uveitis.6	Blindness	is	a	significant	cause	of	morbidity	in	a	population	already	carrying	a	burden	of	psychological	and	systemic	disease.	White	cataract	is	associated	with	hypotony	in	survivors,	and	surgery	in	these	eyes	may	increase	the	risk	of	phthsis	bulbi.81	Cataract	may	develop	in	those	with	or	without	
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uveitis,	and	the	implications	of	viral	persistence	in	the	eye	mean	that	cataract	surgery	is	often	delayed.			Given	the	association	of	cataract	with	uveitis	in	Ebola	survivors,	a	study	of	viral	persistence	in	intraocular	fluid	was	performed	in	50	people	who	were	candidates	for	intraocular	surgery	to	ascertain	the	safety	of	cataract	surgery	in	this	group.79	Of	46	survivors	with	cataract,	three-quarters	had	cataract	surgery.	Median	visual	acuity	improved	from	hand	motions	to	6/9	by	the	4th	postoperative	month.	Five	patients	retained	poor	vision	due	to	vitreoretinal	pathology.	Importantly,	this	study	showed	that	persistence	of	EBOV	in	the	ocular	fluid	was	not	permanent,	as	is	the	case	at	other	immune-privileged	sites.	All	50	Ebola	survivors	tested	negative	for	EBOV	RNA	in	aqueous	and	vitreous	samples,	when	tested	at	a	median	of	18	or	34	months	following	the	acute	disease.		
Conclusion			While	molecular	biological	testing,	including	RT-PCR	and	immunoassays,	are	providing	reliable	means	to	diagnose	the	emerging	viral	forms	of	uveitis,	treatment	of	these	conditions	continues	to	be	challenging.	Corticosteroid	therapies	may	be	effective	in	limiting	the	inflammation.	However,	knowledge	that	the	uveitis	may	reflect	the	presence	of	virus	within	the	eye	means	decisions	around	timing	of	such	treatment	in	the	absence	of	specific	anti-viral	treatment	are	difficult.	Understanding	how	these	viruses	access,	replicate	and	persist	within,	and	finally	are	cleared	from	the	eye	may	provide	a	useful	basis	for	specific	medical	approaches	to	these	diseases.	Initial	studies	using	human	retinal	cells	and	new	in	vivo	models,	most	commonly	in	rodents,	are	providing	
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illuminating	information	in	this	regard.	While	this	work	is	in	its	infancy,	research	from	several	groups	has	focused	on	the	potential	role	of	the	human	retinal	pigment	epithelial	cell	as	a	key	cell	in	providing	access	to	the	eye,	supporting	DENV,	ZIKV	and	EBOV	replication	and	induction	of	a	strong	innate	anti-viral	response.82-84	Studies	of	infections	induced	in	mice	by	local	or	systemic	ZIKV	inoculation	demonstrate	that	Mueller	cells,	as	well	as	retinal	pigment	epithelial	cells,	also	may	be	primary	targets	for	these	viruses.85,86	As	these	investigations	expand,	they	may	identify	opportunities	to	develop	novel	anti-viral	drugs	targeted	at	key	pathogenic	viral	and/or	infected	host	cell	molecules.	
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